NCT04973033View on ClinicalTrials.gov

Effect of Tofacitinib in Treating ANCA-associated Vasculitis

NACompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

December 1, 2019

Primary Completion Date

January 31, 2021

Study Completion Date

January 31, 2021

Conditions
ANCA Associated VasculitisDrug UseJAK-STAT Pathway Deregulation
Interventions
DRUG

Tofacitinib

patients enrolled were prescribed tofacitinib 5mg twice a day orally.

Trial Locations (1)

200032

Department of Rheumatology in Zhongshan hospital, Fudan University, Shanghai

All Listed Sponsors
lead

Shanghai Zhongshan Hospital

OTHER

NCT04973033 - Effect of Tofacitinib in Treating ANCA-associated Vasculitis | Biotech Hunter | Biotech Hunter